Company profile
Manhattan Scientifics, Inc.
OTC: MHTX · Healthcare · Medical - Devices
#1166 of 1,422 Healthcare companies by revenuebottom-decile growth
EA Score
——FH —DQ 50GM —SS 36
v0.1 · 25/100 weight · pillars only
↑ listing tenure, disclosure history · ↓ workforce scale, revenue growth (YoY)
Methodology →Revenue TTM
$2.0k
Rev growth YoY (TTM)
-104.9%
Net income (FY)
-$1.2M
Employees
1
as of 2026-08-29
Market cap
$55.9k
as of 2026-08-29
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02023
Net income-$1.2M-$1.2M2023
Operating income-$703.0k-$703.0k2023
Total assets$316.0k$316.0k2023
Liabilities$2.1M$2.1M2023
Equity-$2.9M-$2.9M2023
Revenue trend
FY2015 – FY2023 · USD
FY15
FY16
FY17
FY19
FY20
FY21
FY22
FY23
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Manhattan Scientifics, Inc.’s revenue?
Manhattan Scientifics, Inc. booked $0 in FY2023 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Thunder Energies Corporation——Eco Science Solutions, Inc.33DCardioGenics Holdings Inc——VIA Pharmaceuticals, Inc.——OneLife Technologies Corp.——Capital Group Holdings, Inc.——Neighbors
New York →Key facts
CEOEmmanuel Tsoupanarias
SectorHealthcare
IndustryMedical - Devices
HeadquartersNew York City, NY
ExchangeOTC: MHTX
Employees1
IPO date1998-01-06
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.